The pill does not blunt resistance-training adaptation: no significant effect on hypertrophy, strength or power across 8 studies
A tight null for hypertrophy, a less tight one for strength, an uninformative one for power
Key Findings
8 studies, n=325 participants, 54 effects, hormonal-contraceptive users versus non-users; 4669 records screened; PROSPERO-registered.
| Adaptation | Pooled effect | 95% CI | p |
|---|---|---|---|
| Hypertrophy | 0.01 | −0.11 to 0.13 | 0.90 |
| Strength | 0.10 | −0.08 to 0.28 | 0.20 |
| Power | −0.04 | −0.93 to 0.84 | 0.80 |
No significant effect of OCP use on any of the three. For hypertrophy the interval is narrow around zero — an informative null. For strength the interval still allows a small effect in favour of pill users, so "no effect" is less certain there.
The power interval (−0.93 to 0.84) is uninformative and should be reported as such rather than as evidence of no effect.
Authors' conclusion: there is no evidence-based rationale to advocate for or against OCP use for hypertrophy, power or strength; an individualised approach considering the individual's response to OCPs, reasons for use and menstrual cycle history may be more appropriate.
All 8 studies were of oral contraceptive pills — no study included other forms of hormonal contraception (implant, injection, hormonal IUS).
Practical Application
Across 8 studies (n=325 women), oral-contraceptive users gained the same muscle size (pooled effect 0.01, 95% CI −0.11 to 0.13) and strength (0.10, −0.08 to 0.28) from resistance training as non-users; the power estimate was too imprecise to read. Do not tell an athlete the pill will cost her gains.
Equally, do not recommend it as a training aid. The null runs in both directions, and contraception is a medical decision made on medical grounds.
Ask which method, not whether. "Hormonal contraception" is many different drugs and this evidence covers only the pill; progestin-only methods draw markedly more reported side effects (REF-574).
⚠️ Refer out for the choice itself. Method selection belongs to the athlete and her physician; the coach's contribution is to stop misinformation about training consequences.
Limitations
8 studies, 325 participants. Small for a question this common, and the power estimate is too imprecise to be usable.
Oral contraceptives only. Implants, injections and hormonal IUS — a large share of real use (REF-574) — are not represented at all.
The studies compared users with non-users rather than randomising women to the pill, so self-selection into pill use cannot be excluded.
Inference, not tested: OCP formulations vary in progestin type and dose; a pooled analysis could hide a formulation-specific effect.
The abstract does not describe the participants' training status or intervention length; nothing here speaks to elite athletes over a season.
Resistance-training outcomes only — endurance adaptation (VO₂max, mitochondrial, haematological) is not addressed here.
How this entry was checked and changed
Why this level
regraded 2026-09-27 from A: meta-analysis of 8 small non-randomised user-vs-non-user comparisons, n=325
Content correction 2026-09-27
Level A -> A- (meta-analysis of 8 small non-randomised user-vs-non-user comparisons).
"Hypertrophy and strength intervals tight enough to exclude anything but a trivial effect" -> true for hypertrophy only; the strength interval (up to 0.28) still allows a small effect favouring users.
Effect metric "SMD" -> "pooled effect" (the abstract does not name the metric); p values added from the abstract.
"Mostly short interventions in mixed training-status women" -> not described in the abstract; relabelled.
Cross-reference description repeated a claim that the cited entry no longer makes (it was corrected against its abstract); description updated to the cited entry's current content.